180秒看懂中國再保險(01508.HK)2021年全年業績亮點
近日,中國再保險(01508.HK)發佈2021年全年業績。2021年,中國再保險(以下簡稱“中再集團”)保費收入穩中有增,集團合併總保費收入為1627.32億元(人民幣,下同);歸屬於母公司股東淨利潤為63.63億元,同比增長11.4%;加權平均淨資產收益率為6.84%;每股分紅0.045元,同比增長9.8%,近期公司股價對應股息率達7.76%。以再保險總保費和淨保費規模計,中再集團全球再保險排名由七進六,躋身2021年《財富》世界500強和全球品牌價值500強,在銀保監會年度公司治理監管評估中名列前茅,境內再保險市場份額穩居第一,主力軍地位持續穩固。
具體業績如何將以短視頻帶您看懂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.